Keywords
How to Cite
Abstract
The literature review is dedicated to analysing the feasibility, efficacy and safety of using brachytherapy in non-small cell lung cancer. A small number of publications highlighting this issue attract attention. It is shown that the method can be implemented with different isotopes and radiation dose rate options from ultra-low to high. There are three main approaches to brachytherapy in thoracic oncology: intraoperative, interstitial and intraluminal. A number of clinical trials, prospective randomised trials and meta-analyses have shown that brachytherapy significantly increases objective response, local control and survival rates in both localised and widespread disease, with acceptable side effects. The focus is on the possibilities of using intraluminal endobronchial brachytherapy in central lung cancer with lesions of the large bronchi and trachea as part of radical, palliative and symptomatic treatment. It has been shown that it is preferable to use equipment with a high dose rate source in order to shorten the duration of the sessions and reduce patient pain. It is a reasonable method when the options of radiotherapy and chemotherapy have been exhausted. It is recommended that the appropriateness of endobronchial brachytherapy be determined on an individual basis. The own data show that median survival in the endobronchial brachytherapy group was 19 months versus 8 months in the no brachytherapy group, 1-year overall survival was 68 % versus 33 %, and 2-year survival was 37 % versus 8 %. One of the indications for palliative use of the method is endobronchial obstruction, especially recurrent. It is recommended that new randomized controlled trials (RCTs) be conducted to evaluate the efficacy and safety of the method. Improvements in brachytherapy outcomes can be achieved through the use of modern high-tech equipment, improved planning systems, radiation dose calculation methods, fractionation mode and optimization of combination with systemic treatment.
References
Мерабишвили В.М., Беляев А.М. Состояние онкологической помощи в россии: однолетняя выживаемость больных злокачественными новообразованиями и летальность на первом году жизни по всем локализациям опухолей. (популяционное исследование на уровне федерального округа). Вопросы онкологии. 2023; 1(69): 55-66.- DOI: 10.37469/0507-3758-2023-69-1-55-66.
[Merabishvili V.M., Belyaev A.M. The state of oncological care in Russia: one-year survival rate of patients with malignant neoplasms and mortality in the first year of life for all tumor localities. (population-based research at the federal district level). Voprosy Onkologii = Problems in Oncology. 2023; 1(69): 55-66.-DOI: https://doi.org/10.37469/0507-3758-2023-69-1-55-66. (In Rus)].
Каприн А.Д. Терапевтическая радиология: национальное руководство. Москва: ГЭОТАР-Медиа. 2018; 704 с. ISBN: 978-5-9704-4658-4.
[Kaprin A.D. Therapeutic radiology: National guidelines. Moscow: GEOTAR-Media. 2018; 704. ISBN 978-5-9704-4658-4. (In Rus)].
Канаев С.В., Арсеньев А.И., Барчук А.С., и др. Лечение опухолевых поражений центральных бронхов и трахеи с использованием эндотрахеобронхиальных операций, внутрипросветной брахитерапии, сочетанной лучевой терапии и химиолучевой терапии. Вопросы онкологии. 2015; 1(61): 62-71.
[Kanaev S.V., Arseniev A.I., Barchuk A.S., et al. Treatment of tumor lesions of the central bronchi and trachea using endotracheobronchial surgery, intraluminal brachytherapy, combined radiotherapy and chemoradiotherapy. Voprosy Onkologii = Problems in Oncology. 2015; 1(61): 62-71. (In Rus)].
Stevens R., Macbeth F., Toy E., et al. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev. 2015; 1(1): CD002143.-DOI: https://doi.org/10.1002/14651858.CD002143.pub4.
Youroukou A., Gkiozos I., Kalaitzi Z., et al. The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review. Clin Transl Oncol. 2017; 19(8): 945-950.-DOI: https://doi.org/10.1007/s12094-017-1635-0.
Skowronek J., Piotrowski T. Brachyterapia nowotworów metoda Pulsed Dose Rate--opis metody oraz przeglad wskazań do leczenia. Pulsed dose rate brachytherapy: a method description and review of clinical application. Przegl Lek. 2002; 59(1): 31-36. (In Pol).
Skowronek J. Pulsed dose rate brachytherapy - is it the right way? J Contemp Brachytherapy. 2010; 2(3): 107-113.-DOI: https://doi.org/10.5114/jcb.2010.16921.
Stewart A., Parashar B., Patel M., et al. American Brachytherapy Society consensus guidelines for thoracic brachytherapy for lung cancer. Brachytherapy. 2016; 15(1): 1-11.-DOI: https://doi.org/10.1016/j.brachy.2015.09.006.
Blasberg J.D., Belsley S.J., Schwartz G.S., et al. Robotic brachytherapy and sublobar resection for T1 non-small cell lung cancer in high-risk patients. Ann Thorac Surg. 2010; 89(2): 360-367.-DOI: https://doi.org/10.1016/j.athoracsur.2009.09.052.
Santos R., Colonias A., Parda D., et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. Surgery. 2003; 134(4): 691-697.-DOI: https://doi.org/10.1016/s0039-6060(03)00327-1.
Patrini D., Lawrence D., Adams B., Panagiotopoulos N. Is brachytherapy effective for local recurrence control in sublobar resections for non-small-cell lung cancer? Interact Cardiovasc Thorac Surg. 2015; 21(5): 677-681.-DOI: https://doi.org/10.1093/icvts/ivv242.
Fernando H.C., Landreneau R.J., Mandrekar S.J., et al. Alliance for Clinical Trials in Oncology. Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. J Thorac Cardiovasc Surg. 2015; 149(3): 718-725.-DOI: https://doi.org/10.1016/j.jtcvs.2014.11.003.
Tselis N., Ferentinos K., Kolotas C., et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol. 2011; 6(3): 545-52.-DOI: https://doi.org/10.1097/JTO.0b013e318208c7a3.
Imamura F., Ueno K., Kusunoki Y., et al. High-dose-rate brachytherapy for small-sized peripherally located lung cancer. Strahlenther Onkol. 2006; 182(12): 703-707.-DOI: https://doi.org/10.1007/s00066-006-1536-6.
Zhang F., Wang J., Guo J., et al. Chinese Expert Consensus Workshop Report: Guideline for permanent iodine‐125 seed implantation of primary and metastatic lung tumors. Thoracic Cancer. 2019; 10: 388-394.-DOI: https://doi.org/10.1111/1759-7714.12912.
Macha H.N., Wahlers B., Reichle C., von Zwehl D. Endobronchial radiation therapy for obstructing malignancies: ten years’ experience with iridium-192 high-dose radiation brachytherapy afterloading technique in 365 patients. Lung. 1995; 173(5): 271-280.
Kelly J.F., Delclos M.E., Morice R.C., et al. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys. 2000; 48(3): 697-702.-DOI: https://doi.org/10.1016/s0360-3016(00)00693-3.
Gejerman G., Mullokandov E.A., Bagiella E., et al. Endobronchial brachytherapy and external-beam radiotherapy in patients with endobronchial obstruction and extrabronchial extension. Brachytherapy. 2002; 1(4); 204-210.-DOI: https://doi.org/10.1016/S1538-4721(02)00098-3.
Celebioglu B., Gurkan O.U., Erdogan S., et al. High dose rate endobronchial brachytherapy effectively palliates symptoms due to inoperable lung cancer. Jpn J Clin Oncol. 2002; 32(11): 443-448.-DOI: https://doi.org/10.1093/jjco/hyf102.
Escobar-Sacristán J.A., Granda-Orive J.I., Gutiérrez Jiménez T., et al. Endobronchial brachytherapy in the treatment of malignant lung tumours. Eur Respir J. 2004; 24(3): 348-352.-DOI: https://doi.org/10.1183/09031936.04.00114902.
Guarnaschelli J.N., Jose B.O. Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience. J Palliat Med. 2010; 13(8): 981-989.-DOI: https://doi.org/10.1089/jpm.2009.0411.
Aumont-Le Guilcher M., Prevost B., Sunyach P., et al. High-dose-rate brachytherapy for non-small-cell lung carcinoma: a retrospective study of 226 patients. Int J Rad Oncol Biol Phys. 2011; 79(4): 1112-1116.-DOI: https://doi.org/10.1016/j.ijrobp.2009.12.041.
de Aquino Gorayeb M.M., Gregório M.G., de Oliveira E.Q., et al. High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment. Brachytherapy. 2013; 12(5): 471-478.-DOI: https://doi.org/10.1016/j.brachy.2012.10.007.
Rochet N., Hauswald H., Stoiber E.M., et al. Primary radiotherapy with endobronchial high-dose-rate brachytherapy boost for inoperable lung cancer: long-term results. Tumori. 2013; 99(2): 183-190.-DOI: https://doi.org/10.1177/030089161309900211.
Goldberg M., Timotin E., Farrell T., et al. A prospective analysis of high-dose-rate endobronchial brachytherapy in the palliation of obstructive symptoms in lung cancer patients: A single-institution experience. Brachytherapy. 2015; 14(5): 655-661.-DOI: https://doi.org/10.1016/j.brachy.2015.04.005.
Soror T., Kovács G., Fürschke V., et al. Salvage treatment with sole high-dose-rate endobronchial interventional radiotherapy (brachytherapy) for isolated endobronchial tumor recurrence in non-small-cell lung cancer patients: a 20-year experience. Brachytherapy. 2019; 18(5): 727-732.-DOI: https://doi.org/10.1016/j.brachy.2019.04.271.
Huber R.M., Fischer R., Haŭtmann H., et al. Palliative endobronchial brachytherapy for central lung tumors. A prospective, randomized comparison of two fractionations schedules. Chest. 1995; 107(2): 463-470.-DOI: https://doi.org/10.1378/chest.107.2.463.
Chella A., Ambrogi M.C., Ribechini A., et al. Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study. Lung Cancer. 2000; 27(3): 169-75.-DOI: https://doi.org/10.1016/s0169-5002(99)00102-6.
Stout R., Barber P., Burt P., et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol. 2000; 56(3): 323-327.-DOI: https://doi.org/10.1016/s0167-8140(00)00252-8.
Marsiglia H., Baldeyrou P., Lartigau E., et al. High-dose-rate brachytherapy as sole modality for early-stage endobronchial carcinoma. Int J Radiat Oncol Biol Phys. 2000; 47(3): 665-672.-DOI: https://doi.org/10.1016/s0360-3016(00)00486-7.
Langendijk H., de Jong J., Tjwa M., et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol. 2001; 58(3): 257-268.-DOI: https://doi.org/10.1016/s0167-8140(00)00345-5.
Sur R., Donde B., Mohuiddin M., et al. Randomized prospective study on the role of high dose rate intraluminal brachytherapy (HDRILBT) in palliation of symptoms in advanced non-small cell lung cancer (NSCLC) treated with radiation alone. Int J Radiat Oncol Biol Phys. 2004; 60: S205.-DOI: https://doi.org/10.1016/j.ijrobp.2004.06.152.
Mallick I., Sharma S.C., Behera D., et al. Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in the palliative management of non-small cell lung cancer: a prospective randomized study. J Cancer Res Ther. 2006; 2(3):P 119-125.-DOI: https://doi.org/10.4103/0973-1482.27586.
Bhattacharya J., Vyas R.K., Saha S., et al. High dose rate endobronchial brachytherapy: Our institutional experience as an effective palliative treatment modality in bronchial carcinoma. Int J Cancer Res Ther. 2017; 2(2): 1-5.
Ung Y.C., Yu E., Falkson C., et al. The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non–small-cell lung cancer: A systematic review. Brachytherapy. 2006; 5(3): 189-202.-DOI: https://doi.org/10.1016/j.brachy.2006.05.001.
Rodrigues G., Videtic G.M., Sur R., et al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011; 1(2): 60-71.-DOI: https://doi.org/10.1016/j.prro.2011.01.005.
Rodrigues G., Macbeth F., Burmeister B., et al. Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. Clin Lung Cancer. 2012; 13(1): 1-5.-DOI: https://doi.org/10.1016/j.cllc.2011.04.004.
Reveiz L., Rueda J.R., Cardona A.F. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2012; 12: CD004284.-DOI: https://doi.org/10.1002/14651858.CD004284.pub3.
Арсеньев А.И., Канаев С.В., Новиков С.Н., и др. Внутрипросветная брахитерапия, дистанционная лучевая терапия и системное лечение при опухолях центральных бронхов и трахеи. Медицинская физика. 2021; 1(89): 9-10.
[Arseniev A.I., Kanaev S.V., Novikov S.N., et al. Intraluminal brachytherapy, remote radiation therapy and systemic treatment for tumors of the central bronchi and trachea. Medicinskaya Fizika = Medical Physics. 2021; 1(89): 9-10. (In Rus)].
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024